Geriatric Nutritional Risk Index is an effective prognostic predictor for metastatic/recurrent or unresectable esophageal cancer receiving immunotherapy
文献类型：期刊论文
| 作者 | Wang, Bei2,4; Wang, Zixuan1,3; Xu, Chuanhai2; Wang, Yueqin2; Gao, Honglan2; Liu, Haiping2; Zheng, Mingyue4,6 ; Jiang, Zhenyuan1,3; Zhou, Zini2,3; Liu, Gui2,5
|
| 刊名 | JOURNAL OF GASTROINTESTINAL ONCOLOGY
 |
| 出版日期 | 2025-02-28 |
| 卷号 | 16期号:1页码:22 |
| 关键词 | Geriatric Nutritional Risk Index (GNRI) esophageal squamous cell carcinoma (ESCC) immune checkpoint inhibitors (ICIs) programmed cell death ligand 1 (PD-L1) |
| ISSN号 | 2078-6891 |
| DOI | 10.21037/jgo-24-722 |
| 英文摘要 | Background: Immune checkpoint inhibitors (ICIs) have been extensively utilized in the treatment of esophageal squamous cell carcinoma (ESCC); however, patient responses to these therapies exhibit significant variability. This study aimed to investigate the prognostic value of Geriatric Nutritional Risk Index (GNRI) in patients with ESCC undergoing immunotherapy. Methods: A retrospective study was conducted on 677 patients with metastatic/recurrent or unresectable ESCC who received immunotherapy. Kaplan-Meier analysis and Log-rank test compared survival differences between high and low GNRI groups, while Cox proportional hazards models analyzed the impact of GNRI on survival in various subgroups and identified independent prognostic factors. Furthermore, immunohistochemistry (IHC) was performed on endoscopic biopsy tissues from 45 patients with unresectable disease who received immune ICIs as first-line treatments to investigate the predictive performance of GNRI combined with programmed cell death ligand 1 (PD-L1) for tumor response and overall survival (OS). Results: Regardless of metastatic/recurrent disease or unresectable status, patients with high GNRI levels had significantly longer OS time (P<0.001). Moreover, the protective role of GNRI was observed in various subgroups. Eastern Cooperative Oncology Group performance status (ECOG PS) score, distant organ metastasis, previous treatments, ICI modalities and GNRI were identified as independent prognostic factors for OS. Furthermore, the predictive performance of GNRI for OS may surpass that of PD-L1 expression (P=0.009 vs. P=0.38), while PD-L1 expression excelled in predicting tumor response (P=0.007 vs. P=0.08). The combination of these two indicators effectively predicted both tumor response (P=0.04) and OS (P=0.03) in immunotherapy. Conclusions: The GNRI serves as a robust prognostic indicator in patients with ESCC who are treated with ICIs. The integration of PD-L1 expression and GNRI demonstrates significant predictive value for tumor response and OS. |
| WOS关键词 | IMMUNE CHECKPOINT INHIBITORS ; SQUAMOUS-CELL CARCINOMA ; ADENOCARCINOMA ; CHEMOTHERAPY ; EFFICACY ; THERAPY |
| 资助项目 | Jiangsu Province Traditional Chinese Medicine Science and Technology Development Program[YB2020079] ; Project of National Clinical Research Base of Traditional Chinese Medicine in Jiangsu Province, China[JD2023SZX14] ; Project of Jiangsu Health Commission[Z2022016] ; Yancheng Medical Science and Technology Development Program Project[YK2021025] |
| WOS研究方向 | Oncology ; Gastroenterology & Hepatology |
| 语种 | 英语 |
| WOS记录号 | WOS:001446702000001 |
| 出版者 | AME PUBLISHING COMPANY |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/316695]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Geng, Wei |
| 作者单位 | 1.Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Radiotherapy, Nanjing, Peoples R China 2.First Peoples Hosp Yancheng, Dept Radiotherapy, 66 South Peoples Rd, Yancheng 224000, Peoples R China 3.Xuzhou Med Univ, Xuzhou, Peoples R China 4.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing, Peoples R China 5.Jiangsu Univ, Sch Med, Zhenjiang, Peoples R China 6.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Bei,Wang, Zixuan,Xu, Chuanhai,et al. Geriatric Nutritional Risk Index is an effective prognostic predictor for metastatic/recurrent or unresectable esophageal cancer receiving immunotherapy[J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY,2025,16(1):22. |
| APA | Wang, Bei.,Wang, Zixuan.,Xu, Chuanhai.,Wang, Yueqin.,Gao, Honglan.,...&Geng, Wei.(2025).Geriatric Nutritional Risk Index is an effective prognostic predictor for metastatic/recurrent or unresectable esophageal cancer receiving immunotherapy.JOURNAL OF GASTROINTESTINAL ONCOLOGY,16(1),22. |
| MLA | Wang, Bei,et al."Geriatric Nutritional Risk Index is an effective prognostic predictor for metastatic/recurrent or unresectable esophageal cancer receiving immunotherapy".JOURNAL OF GASTROINTESTINAL ONCOLOGY 16.1(2025):22. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。